{"id":"W2592234056","doi":"10.1182/blood.v128.22.1107.1107","title":"Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Clinical endpoint; Brentuximab vedotin; Phases of clinical research; Refractory (planetary science); Cohort; Chemotherapy regimen; Lymphoma; Chemotherapy; Cancer; Clinical trial; Immunotherapy; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006836065,0.001285142,0.001942383,0.0003905635,0.0003329148,0.001400232,0.0009625885,0.001205065,0.002850501],"category_scores_gemma":[0.00321311,0.0005586162,0.00265312,0.0006120793,0.0004565615,0.0008736132,0.0008104004,0.001927571,0.0005703269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009140848,"about_ca_system_score_gemma":0.001247326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004595479,"about_ca_topic_score_gemma":0.00116108,"domain_scores_codex":[0.9975038,0.00166907,0.0001020607,0.0003236517,0.0002273418,0.0001740661],"domain_scores_gemma":[0.9978861,0.0005350841,0.0006588522,0.0002449384,0.0002713112,0.0004035936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8846772,0.006806496,0.04162386,0.002189162,0.01595314,0.0002037272,0.0001117495,0.002279902,0.009019721,0.0004237432,0.006055549,0.0306557],"study_design_scores_gemma":[0.6828465,0.1229738,0.1584955,0.000325838,0.0181628,0.0005589798,0.0001423272,0.003610272,0.002647028,0.0007569057,0.009382945,0.00009711556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740945,0.007520588,0.00116941,0.000702376,0.0001491636,0.003249862,0.009889978,0.00008808352,0.003136043],"genre_scores_gemma":[0.9731442,0.002138857,0.001755149,0.001400453,0.0002898734,0.004705148,0.01507423,0.00004704798,0.001445046],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006836065,"threshold_uncertainty_score":0.03615302,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01326816067492311,"score_gpt":0.2703291171265829,"score_spread":0.2570609564516598,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}